What are the most common prenatal ultrasound findings in a fetus with Type 1 (Spinal Muscular Atrophy) SMA?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prenatal Ultrasound Findings in Fetuses with Type 1 Spinal Muscular Atrophy

The most common prenatal ultrasound findings in fetuses with Type 1 spinal muscular atrophy (SMA) include decreased fetal movements, polyhydramnios, and joint contractures, though these findings may not be evident until later in pregnancy and are often absent in the first and early second trimesters.

Timing of Detection

  • Most severe neuromuscular disorders like SMA Type 1 are typically detected during the routine ultrasound performed at 18-20 weeks of gestation 1
  • Increased nuchal translucency at 10-14 weeks of gestation can be an early sign of severe neuromuscular disorders, though this is not specific to SMA 1

Specific Ultrasound Findings in SMA Type 1

  • Decreased fetal movements are a hallmark finding, particularly in the third trimester, though studies have shown that movements may appear normal in the first and early second trimesters 2, 3
  • Polyhydramnios may develop due to impaired fetal swallowing as a result of bulbar muscle weakness 4
  • Joint contractures (arthrogryposis) may be observed due to prolonged immobility in utero 4, 3
  • Small or bell-shaped thorax may develop as respiratory muscles are affected 1

Limitations in Early Detection

  • Studies examining fetuses at risk for severe SMA at 11-14 weeks gestation found no qualitative limitation of movements, even in fetuses predicted to develop severe neonatal forms 2
  • This suggests that the pathological process in SMA Type 1 may not significantly affect fetal movements until later in pregnancy 2, 4
  • Early prenatal diagnosis typically relies on genetic testing rather than ultrasound findings 4, 3

Prognostic Indicators

  • When SMA is suspected, several ultrasound parameters can help predict severity and outcomes:
    • Chest to abdomen ratio <0.6 suggests pulmonary hypoplasia and poor prognosis 1
    • Presence of hydrops fetalis indicates severe disease 1
    • Severely decreased mineralization of the axial skeleton may be observed in severe cases 1

Diagnostic Approach

  • When decreased fetal movements or other suspicious findings are detected:
    • A detailed anatomical survey should be performed 1
    • Genetic testing for SMN1 gene deletion should be offered 4, 3
    • The number of SMN2 gene copies should be determined as this correlates with disease severity 3

Common Pitfalls

  • SMA Type 1 may be missed on routine ultrasound screening, particularly in early pregnancy when fetal movements appear normal 2, 4
  • Decreased fetal movements may be attributed to other causes or considered subjective 3
  • The diagnosis requires a high index of suspicion, especially in families with no prior history of SMA 4

Differential Diagnosis

  • Other conditions that can present with decreased fetal movements include:
    • Other neuromuscular disorders
    • Skeletal dysplasias
    • Central nervous system anomalies
    • Chromosomal abnormalities 1, 5

Understanding these ultrasound findings is crucial for early detection and appropriate counseling of families affected by SMA Type 1, though genetic testing remains the gold standard for definitive diagnosis.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Prenatal onset spinal muscular atrophy.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.